DexCom, Inc. (NASDAQ:DXCM) Stock Rated "Moderate Buy" by Wall Street Brokerages

Key Points

• DexCom has a “Moderate Buy” consensus rating from 26 analysts, with 21 buy ratings and two strong-buy ratings. The average 12-month price target is $89.08.
• DexCom exceeded quarterly expectations, reporting EPS of $0.70 versus $0.61 estimated and revenue of $1.31 billion, up 13.1% year over year.
• Insiders sold 73,504 shares worth approximately $5.65 million over the past 90 days, while institutional investors own a substantial 97.75% of the company.

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty-six ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twenty-one have issued a buy rating and two have given a strong buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $89.08.

Several analysts have issued reports on DXCM shares. Wall Street Zen raised shares of DexCom from a "hold" rating to a "buy" rating in a research report on Sunday, September 6th. Canaccord Genuity Group set a $90.00 price objective on shares of DexCom and gave the company a "buy" rating in a research report on Monday, August 3rd. Mizuho boosted their price objective on shares of DexCom from $90.00 to $95.00 and gave the stock an "outperform" rating in a research note on Friday, July 31st. Citigroup reaffirmed a "buy" rating and issued a $88.00 target price (up from $84.00) on shares of DexCom in a report on Friday, July 31st. Finally, Benchmark raised their target price on shares of DexCom from $77.00 to $82.00 and gave the company a "buy" rating in a research note on Friday, July 31st.

DexCom Stock Down 0.3%

DXCM stock opened at $87.47 on Friday. The company has a market cap of $33.01 billion, a price-to-earnings ratio of 34.57, a P/E/G ratio of 1.50 and a beta of 1.42. DexCom has a twelve month low of $54.11 and a twelve month high of $92.59. The business has a 50 day moving average price of $85.16 and a two-hundred day moving average price of $73.77. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.61 by $0.09. The company had revenue of $1.31 billion for the quarter, compared to analysts' expectations of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The business's revenue was up 13.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.48 EPS. Analysts anticipate that DexCom will post 2.64 EPS for the current fiscal year.

Insider Transactions at DexCom

In other news, Director Nicholas Augustinos sold 6,539 shares of the firm's stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total value of $549,537.56. Following the completion of the sale, the director directly owned 29,293 shares of the company's stock, valued at $2,461,783.72. This trade represents a 18.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jereme M. Sylvain sold 3,638 shares of DexCom stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $83.27, for a total value of $302,936.26. Following the transaction, the executive vice president owned 146,828 shares of the company's stock, valued at $12,226,367.56. This represents a 2.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 73,504 shares of company stock valued at $5,651,332. Company insiders own 0.28% of the company's stock.

Hedge Funds Weigh In On DexCom

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Reflection Asset Management acquired a new stake in shares of DexCom during the 4th quarter worth about $25,000. Ascentis Independent Advisors acquired a new position in DexCom in the 1st quarter valued at about $25,000. MCF Advisors LLC acquired a new position in shares of DexCom in the fourth quarter valued at approximately $32,000. Wellington Grp LLC grew its position in shares of DexCom by 778.7% in the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company's stock valued at $34,000 after purchasing an additional 475 shares during the last quarter. Finally, Cassaday & Co Wealth Management LLC bought a new position in shares of DexCom during the first quarter worth approximately $44,000. 97.75% of the stock is owned by institutional investors.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company's products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.